|
    BNTX U.S.: Nasdaq

    BioNTech SE ADR

    BNTXUS
    Open
    Back To Top
    Last Updated: Jun 23, 2021 10:11 a.m. EDT Real time quote

    $ 231.00

    -5.49 -2.32%
    Previous Close
    $236.49
    Advanced Charting
    • $
    • %
    • Vol
    Volume: 501.39K 65 Day Avg: 3M
    17% vs Avg
    225.07 Day Range 238.00
    51.81 52 Week Range 252.78

    Your Watchlists

    Customize eLesor

    Have Watchlists? Log in to see them here or sign up to get started.

    Symbol
    Company
    Price
    Chg/Chg %
    No Items in Watchlist

    There are currently no items in this Watchlist.

    Uh oh

    Something went wrong while loading Watchlist.

    Recently Viewed Tickers

    No Recent Tickers

    Visit a quote page and your recently viewed tickers will be displayed here.

    BNTX Overview

    Performance

    5 Day
    • 13.32%
    1 Month
    • 14.15%
    3 Month
    • 145.61%
    YTD
    • 183.37%
    1 Year
    • 322.07%

    Analyst Ratings

    • Sell
    • Under
    • Hold
    • Over
    • Buy
    Number of Ratings 13 Full Ratings

    Recent News

    • eLesor
    • Dow Jones

    Siemens, BioNTech to Expand Vaccine Production Collaboration

    Read full story

    Fauci Calls Delta Variant the “Greatest Threat” to Defeating Coronavirus

    Read full story

    From ‘Death Cross’ to a Near Bull Market: Bitcoin’s Wild Ride

    Go to video

    How COVID vaccine's mRNA technology could help cure other diseases

    Read full story

    BioNTech SE ADR rises Tuesday, outperforms market

    Read full story

    WHO warns poorer countries are not getting fair share of COVID vaccine supply, as Colombia passes 100,000 deaths

    EU Approves Two More Manufacturing Sites for Pfizer-BioNTech Covid Vaccine

    Read full story

    BioNTech SE ADR outperforms market on strong trading day

    Read full story

    30 states likely to miss President Biden’s July 4 vaccination goal, and Brazil’s death toll has topped 500,000

    Read full story

    U.S. moves to fill gap in treatments for COVID, as Delta variant creates worrying spike in new cases in the U.K.

    Read full story

    BioNTech SE ADR outperforms market despite losses on the day

    Curevac shares climb 10%; CFO says not giving up on COVID-19 vaccine

    Read full story

    Four COVID-19 vaccines are being tested in children and teens. Here’s when different age groups could become eligible for shots.

    Canada Vaccine Panel Recommends Against AstraZeneca PLC for Second Dose

    Read full story

    BioNTech CEO Warns Delta Variant Could Lead to a Covid-19 Resurgence

    Read full story

    CureVac Stock Fell 39% After Its Vaccine Failure. The Pain May Just Be Getting Started.

    Read full story

    BioNTech SE ADR outperforms competitors on strong trading day

    Go to video

    BioNTech CEO on Vaccine Booster Shots and the Risk of a Fourth Wave

    Read full story

    CureVac says its COVID vaccine was poor match against 29 COVID variants, as global case tally tops 177 million

    Read full story

    Join Barron’s Investing in Tech Conference to Hear From the CEOs of Palantir, BioNTech, and Others

    • Other News
    • Press Releases

    How Pfizer and Moderna Could Profit Big-Time From AstraZeneca's and CureVac's Challenges

    on Motley Fool

    Why BioNTech Trounced the Market on Tuesday

    on Motley Fool

    If You Thought These 2 Big Nasdaq Winners Were Done, Think Again

    on Motley Fool

    Why BioNTech Stock Is Rising Today

    on Motley Fool

    BioNTech Begins Patient Dosing in Phase 2 Cancer Vaccine Trial

    on TipRanks.com

    Will Emergence of COVID-19 Delta Variant Aid Vaccine Makers?

    on Zacks.com

    Pfizer Vaccine Approved for 12-15-Year Olds in New Zealand – Report

    on TipRanks.com

    Why Is Everyone Talking About CureVac Stock?

    on Motley Fool

    Novavax Is a Long-Term Buy for the Continuing Pandemic

    on InvestorPlace.com

    Is Now the Time to Go All-In On Novavax Stock?

    on Motley Fool

    Pfizer's COVID Vaccine Is Even More Amazing Than You Think

    on Motley Fool

    Biogen (BIIB) Initiates Late-Stage Study on Lupus Candidate

    on Zacks.com

    Why BioNTech, Moderna, and Novavax Stocks Sank This Week

    on Motley Fool

    Why CureVac Stock Is Getting Crushed Today

    on Motley Fool

    Aprea (APRE) Stock Rises as Leukemia Triplet Meets Study Goal

    on Zacks.com

    CVAC Stock: The Huge Covid-19 News That Has CureVac Plunging Today

    on InvestorPlace.com

    Ocugen (OCGN) Selects Coronavirus Vaccine Manufacturer in US

    on Zacks.com

    Why BioNTech Stock Was Sliding Today

    on Motley Fool

    Is There Still Upside Potential for Novavax Stock?

    on InvestorPlace.com

    Axsome (AXSM) Plans NDA Filing for Fibromyalgia Drug in 2022

    on Zacks.com

    BioNTech SE ADR

    BioNTech SE operates as a clinical-stage biotechnology company. It operates through the following business units: Biotech Business and External Services. The Biotech Business unit consists of Clinical, Technology Platform and Manufacturing segments. It also includes business services operations. The External Services unit consists of External Services segment, which includes activities related to the sale of diagnostic products, peptides, retroviral vectors for clinical supply, development and manufacturing services. The company was founded by Christopher Huber, Ozlem Tureci and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.